• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media.

作者信息

Hamada Satoshi, Ogino Eriko, Yasuba Hirotaka

机构信息

Department of Respiratory Medicine, Hikone Municipal Hospital, Hikone, Japan.

Kyoto Station-front Ear Nose and Allergy Clinic, Kyoto, Japan.

出版信息

Allergol Int. 2021 Jul;70(3):389-391. doi: 10.1016/j.alit.2021.02.002. Epub 2021 Mar 6.

DOI:10.1016/j.alit.2021.02.002
PMID:33685801
Abstract
摘要

相似文献

1
Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media.使用贝那利珠单抗和度普利尤单抗进行循环疗法治疗伴有嗜酸性慢性鼻-鼻窦炎和嗜酸性中耳炎的重度嗜酸性粒细胞性哮喘。
Allergol Int. 2021 Jul;70(3):389-391. doi: 10.1016/j.alit.2021.02.002. Epub 2021 Mar 6.
2
Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.度普利尤单抗治疗伴有支气管哮喘的难治性嗜酸粒细胞性中耳炎患者。
Auris Nasus Larynx. 2021 Jun;48(3):353-360. doi: 10.1016/j.anl.2020.09.001. Epub 2020 Sep 14.
3
IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.IL13 可能在嗜酸性慢性鼻鼻窦炎和伴有严重哮喘的嗜酸性中耳炎的发展中发挥重要作用。
Int J Mol Sci. 2021 Oct 18;22(20):11209. doi: 10.3390/ijms222011209.
4
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.美泊利珠单抗治疗重症哮喘伴嗜酸性慢性鼻-鼻窦炎患者的疗效。
BMC Pulm Med. 2019 Oct 12;19(1):176. doi: 10.1186/s12890-019-0952-1.
5
Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.贝那鲁肽对伴有严重哮喘的变应性慢性鼻-鼻窦炎和鼻息肉的实际影响。
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420950851. doi: 10.1177/2058738420950851.
6
Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab.使用度普利尤单抗成功治疗合并严重哮喘的嗜酸性粒细胞性慢性鼻-鼻窦炎，此前使用贝那利珠单抗治疗初治结果为阴性。
Allergol Int. 2021 Jan;70(1):150-152. doi: 10.1016/j.alit.2020.05.002. Epub 2020 Jun 4.
7
Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology?两例伴有嗜酸性慢性鼻-鼻窦炎的哮喘患者中与度普利尤单抗相关的嗜酸性肺炎：是白细胞介素-5驱动的病理改变吗？
Allergol Int. 2022 Oct;71(4):548-551. doi: 10.1016/j.alit.2022.03.005. Epub 2022 Apr 18.
8
[SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB].[使用抗IL-5受体单克隆抗体贝那利珠单抗成功治疗与嗜酸性肉芽肿性多血管炎相关的中耳炎和鼻窦炎]
Arerugi. 2022;71(3):242-247. doi: 10.15036/arerugi.71.242.
9
Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.将生物疗法转换为度普利尤单抗治疗合并严重哮喘和 CRSwNP 的患者。
Eur Arch Otorhinolaryngol. 2024 Jun;281(6):3017-3023. doi: 10.1007/s00405-024-08461-y. Epub 2024 Feb 12.
10
[Eosinophilic chronic rhinosinusitis and eosinophilic otitis media].
Arerugi. 2011 May;60(5):535-45.

引用本文的文献

1
Biologic Therapy Relieves Otologic Symptoms and Signs in Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps.生物疗法可缓解哮喘和伴有鼻息肉的慢性鼻-鼻窦炎患者的耳科症状和体征。
Laryngoscope Investig Otolaryngol. 2025 Jul 24;10(4):e70212. doi: 10.1002/lio2.70212. eCollection 2025 Aug.
2
Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases.联合双生物制剂治疗重度哮喘：十例系列病例
J Asthma Allergy. 2025 Apr 5;18:507-517. doi: 10.2147/JAA.S507008. eCollection 2025.
3
Combination Biologic Therapy with Mepolizumab and Dupilumab for Severe Eosinophilic Granulomatosis with Polyangiitis and Chronic Rhinosinusitis with Nasal Polyp.
美泊利单抗和度普利尤单抗联合生物疗法治疗严重嗜酸性肉芽肿性多血管炎和伴鼻息肉的慢性鼻-鼻窦炎
Yonago Acta Med. 2024 Apr 17;67(2):157-162. doi: 10.33160/yam.2024.05.005. eCollection 2024 May.
4
Combination of Biological Therapy in Severe Asthma: Where We Are?重度哮喘生物治疗的联合应用：我们目前的进展如何？
J Pers Med. 2023 Nov 10;13(11):1594. doi: 10.3390/jpm13111594.
5
Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study.倍利珠单抗治疗重度嗜酸性粒细胞性哮喘患者的长期疗效及临床缓解：一项回顾性研究
J Asthma Allergy. 2022 Nov 29;15:1731-1741. doi: 10.2147/JAA.S391807. eCollection 2022.
6
Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media.针对伴鼻旁窦炎和中耳炎的嗜酸性哮喘患者的 IL-5 和 IL-4/13 的序贯生物疗法。
Biomolecules. 2022 Mar 30;12(4):522. doi: 10.3390/biom12040522.
7
Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.生物制剂对与支气管哮喘或严重未控制的慢性鼻-鼻窦炎伴鼻息肉相关的难治性嗜酸性粒细胞性中耳炎的疗效。
J Clin Med. 2022 Feb 10;11(4):926. doi: 10.3390/jcm11040926.
8
IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.IL13 可能在嗜酸性慢性鼻鼻窦炎和伴有严重哮喘的嗜酸性中耳炎的发展中发挥重要作用。
Int J Mol Sci. 2021 Oct 18;22(20):11209. doi: 10.3390/ijms222011209.